Over the last 12 months, one Forte Biosciences, Inc. officers and board members bought into shares on the open market, about $255,000 in total, and none of them sold.
Riley Antony A (CFO) made the biggest buy, worth around $255,000. Notably, at least one C-suite executive was among the buyers.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Riley Antony A | CFO | Buy | 9,680 | $26.33 | $255K | SEC |
| Nov 22, 2024 | Riley Antony A | CFO | Buy | 22,514 | $5.55 | $125K | SEC |
| Dec 20, 2023 | Wagner Paul A. | Officer | Buy | 10,000 | $0.75 | $8K | SEC |
| Dec 15, 2023 | Wagner Paul A. | Officer | Buy | 10,520 | $0.70 | $7K | SEC |
| Dec 15, 2023 | Wagner Paul A. | Officer | Buy | 10,000 | $0.72 | $7K | SEC |
| Dec 12, 2023 | Wagner Paul A. | Officer | Buy | 25,000 | $0.65 | $16K | SEC |
| Dec 12, 2023 | Wagner Paul A. | Officer | Buy | 4,776 | $0.65 | $3K | SEC |
| Dec 8, 2023 | Wagner Paul A. | Officer | Buy | 36,203 | $0.58 | $21K | SEC |
| Dec 8, 2023 | Wagner Paul A. | Officer | Buy | 15,000 | $0.62 | $9K | SEC |
| Nov 22, 2023 | Wagner Paul A. | Officer | Buy | 5,300 | $0.44 | $2K | SEC |
| Nov 22, 2023 | Wagner Paul A. | Officer | Buy | 400 | $0.43 | $172 | SEC |
| Nov 22, 2023 | Wagner Paul A. | Officer | Buy | 100 | $0.43 | $43 | SEC |
| Nov 22, 2023 | Wagner Paul A. | Officer | Buy | 1,566 | $0.43 | $673 | SEC |
In the last 12 months Forte Biosciences, Inc. insiders made open-market purchases worth about $255,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in FBRX was filed on 2026-01-02.
No congressional trades in FBRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).